Across TCGA pan-cancer cohorts, TAS2R50 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated TAS2R50 data layer compared with 3 for mutation status.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TAS2R50 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TAS2R50 expression acts as an unfavorable survival marker, although some lineages such as THYM and SCLC show a favorable association.
ACC, COAD, and STAD are the cancer types where TAS2R50 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.